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Cationic antimicrobial peptides (AMPs) represent the first line of defense against many invading pathogens. These small 
amphipathic peptides are part of the innate immune system and have a broad-spectrum activity against bacteria, fungi and 
viruses. In mammals, at least two distinct groups of AMPs are found. Defensins are the more representatives and 
cathelicidins form the second group. The hCAP18/LL37 is the only known human cathelicidin. The antimicrobial peptide 
is referred to as LL37, since it has a 37 amino acids sequence starting with two leucines. It is a 4.5 kDa, cationic (+6), 
amphipathic α-helical peptide, with a broad spectrum of antimicrobial activity. Besides its antimicrobial properties LL37 
plays a central role in innate immune responses and inflammation. It has been identified as a potent chemoattractant for 
mast cells, monocytes, T lymphocytes and neutrophils using formyl-peptide receptor–like 1 (FPRL1). LL37 also promotes 
wound healing, angiogenesis and arteriogenesis and acts as immune adjuvant. 
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1. Antimicrobial Peptides 
The increasing bacterial resistance against common antibiotics is a growing concern for the public health. Resistance 
began to emerge as early as the 1950s with multiresistant microorganisms such as Staphylococcus aureus, 
Pseudomonas aeruginosa or Enterococcus sp., largely as the result of antibiotic overuse [1].  
 Much research has been dedicated to the development of new classes of antibiotics to overcome bacterial resistance. 
The focus on the structure and function of antimicrobial peptides (AMPs) has greatly increased in recent years. AMPs 
are an important part of the innate immune system of most living organisms against invading pathogens, playing a 
direct antimicrobial and mediator function and providing the initial host defense mechanism. They are generally defined 
as peptides of less than 50 amino acid residues, bearing positive charge due to multiple lysine and arginine residues and 
with 50% or more of hydrophobic residues [2]. AMPs have aroused great interest due to their broad spectrum of 
antimicrobial activity against Gram-positive and Gram-negative bacteria [3], fungi [4] and protozoa [5] with minimum 
inhibitory concentrations (MIC) as low as 0.25-0.4 µg/ml [6]. Certain cationic peptides have been shown to inhibit the 
replication of enveloped viruses such as influenza A virus [7], vesicular stomatitis virus (VSV) and human 
immunodeficiency virus (HIV-1) [8]. Moreover, these peptides have potential to overcome bacterial resistance [9]. 
Therefore, AMPs or their derivatives can potentially represent a new class of antimicrobial drugs. 
AMPs can be grouped according to their size, conformational structure or predominant amino acid structure; 
nevertheless, the diversity of these molecules is so great that it is difficult to categorize them in a generally accepted 
classification. On the basis of their 3D structure, peptide antibiotics can be classified in four major groups, with the first 
two being the most common in nature [6]: 
 •   Group I: β-sheet structures stabilized by disulfide bridges. 
 •   Group II: linear peptides with a α-helical structure. 
 •   Group III: extended peptides. 
 •   Group IV: peptides with loop structures. 
 
 The exact mechanism by which AMPs exert their antimicrobial properties is yet unclear, but it is generally accepted 
that cationic AMPs interact by electrostatic forces with the negatively charged phospholipids on the bacterial 
membrane. The interaction is complex and results in the creation of pores and membrane disruption. There are several 
mechanisms proposed, the most widely accepted being the “barrel-stave”, “carpet” and “toroidal” models [10].  
The “barrel-stave” model describes the formation of transmembrane channel/pores by groups of amphipathic α-helical 
peptides, where the hydrophobic surfaces interact with the aliphatic chain of the membrane phospholipids and the 
hydrophilic parts point inside producing an aqueous pore [11].  
 In the “carpet model”, peptides accumulate on the bilayer surface. Peptides are electrostatically attracted to the 
anionic phospholipid head groups at numerous sites covering the surface of the membrane in a carpet-like manner. At 
high peptide concentrations, surface-oriented peptides are thought to disrupt the bilayer by acting like a detergent, 
eventually leading to the formation of micelles [12]. 
 In the “toroidal-pore model”, antimicrobial peptide helices insert into the membrane and induce the lipid monolayers 
to bend continuously through the pore so that the water core is lined by both the inserted peptides and the lipid head 
groups. This type of transmembrane pore is induced by magainins, protegrins and melittin[13, 14]. The “toroidal” 
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model differs from the “barrel-stave model” as the peptides are always associated with the lipid head groups even when 
they are perpendicularly inserted into the lipid bilayer. 
2. The human cathelicidin LL37 
There are two major groups of antimicrobial peptides in humans: defensins and cathelidicins. All cathelicidins share a 
similar structure characterized by a highly conserved N-terminal domain of about 100 amino acid residues. This 
cathelin-like domain is flanked by a signal peptide (approximately 30 residues long) on its N-terminus, and by an 
antimicrobial peptide region on its C-terminus.  
2.1 Structure and cellular expression of LL37 
The only member of the cathelicidins family found to date in humans is LL37/hCAP18, an 18 kDa peptide encoded by 
the gene CAMP (GeneBank ID 820). It was first described in 1995 in bone marrow cells [15]. The name hCAP18 was 
chosen because of its close relationship to the cationic antimicrobial peptide found in rabbit, which has a molecular 
weight of 18 kDa and is therefore called Cationic Antimicrobial Peptide CAP18. The gene for the human cathelicidin 
hCAP18 is a compact gene of 1963 bp located in chromosome 3, and is composed of four exons. Exons 1 to 3 code for 
the signal sequence and the cathelin domain, while exon 4 codes for the antimicrobial peptide [16] (figure 1).  
 
Fig.1 Schematic structure of the LL37/hCAP18 gene and its processing into LL37 peptide. 
 
 
 The mature antimicrobial peptide has 37 amino acid residues starting with two leucines (NH2-
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES-COOH), hence being named LL37. It does not contain any 
cysteine or tryptophan residue and has a molecular weight of ~4.5 kDa. The peptide is derived by extracellular 
proteolysis of proteinase 3 from the C-terminal end of hCAP18 [17], differing from most cathelicidins that are cleaved 
by elastase [18, 19]. Initially, the active mature peptide was considered to be the 39-residue FALL39, based on the 
presence of a typical KR cleavage site [20]. However, Gudmundsson et al.[16] used anti-FALL39 imunoglobulin to 
locate the mature peptide and isolated it from granulocytes after degranulation. The structural analysis determined the 
mature peptide to be LL37. Nevertheless, two research groups have described other processed peptides. Sorensen et al. 
reported that hCAP-18 in seminal plasma is processed to generate the 38-amino acid antimicrobial peptide ALL38 by 
the prostate-derived protease gastricsin, when incubated at the vaginal pH. Indeed, ALL38 was found in the vagina 
following sexual intercourse and the antimicrobial activity of ALL38 against a variety of microorganisms tested was 
equivalent to that of LL37 [21]. Murakami et al. [22] and Yamasaki et al. [23] showed that after secretion onto the skin 
surface or sweat, the CAMP gene product is processed by a serine protease-dependent mechanism into multiple novel 
antimicrobial peptides distinct from the cathelicidin LL37. These peptides (RK31, KS30, LL29, KS22 and KR20) 
showed enhanced antimicrobial action, acquiring the ability to kill skin pathogens such as Staphylococcus aureus and 
Candida albicans. 
 At physiological pH, LL37 has a positive net charge of +6. The peptide has 6 lysines and 5 arginines that carry 11 
positive charges, while 3 glutamates and 2 aspartates residues bear 5 negative charges. It is relatively disordered in 
aqueous solution, but folds into an amphipathic -helix in other environments, such as in contact with lipid membranes 
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[24]. Guangshun Wang studied the structure of 13C,15N-labeled LL37 by three-dimensional triple-resonance NMR and 
reported that the helical region covers residues 2 to 30, while the C-terminus is mobile [25]. All antimicrobial peptides 
are amphipathic, meaning that they have hydrophobic and hydrophilic regions, allowing the electrostatic interaction 
with anionic bacterial membranes. Figure 2 illustrates the three-dimensional structure of LL37. The hydrophobic 
residues are shown in red and are aligned on one side of the peptide. 
 
 
Fig.2α-helical structure of LL37. Hydrophobic residues are shown in red. 
 
 
 LL37 and its precursor, hCAP18, are found at different concentrations in very different cells, tissues and body fluids, 
predominantly in leukocytes and various epithelial linings. But the expression of hCAP18/LL37 has been reported in 
many other tissues or body fluids like breast milk, sweat, wound fluids, saliva, gingiva, testis, spermatozoa, seminal 
plasma, amniotic fluids and more, as well summarized by Durr et al.[20]. In a recent work, Laudien et al. also reported 
the expression of LL37 and defensins in the nasal epithelium providing a chemical defense shield [26]. AMPs are also 
present in ear wax preventing bacteria and fungi from causing infections in the external auditory canal [27]. The 
quantification of hCAP18/LL37 concentrations in vivo is challenging. Sorensen et al. developed a specific ELISA for 
the detection of hCAP18 in cells, plasma and urine. They determined that the amount of hCAP18 in neutrophils is 0.627 
µg/106 cells and is barely excreted in the urine. The plasma level is 1.18 µg/ml, several fold higher than for other 
neutrophil specific granule proteins [28]. In the airway fluids, the levels of LL37 are estimated to be 2 µg/ml in adults 
and 5 µg/ml in neonates.  
 The down and upregulation of LL37 have been identified in many diseases. A higher concentration of the peptide is 
more common in the presence of infections. In fact, in pulmonary infections the levels of LL37 are augmented two or 
three times [29]. A low expression of LL37 is associated with skin disorders like atopic dermatitis [30] or chronic ulcers 
[31]. Putsep et al.[32] reported that the neutrophils from patients with morbus Kostmann syndrome are deficient in 
LL37. However, in acute inflammation, LL37 concentrations can dramatically increase, reaching 1.5 mg/ml in the skin 
lesions of psoriasis patients [33]. High concentrations of LL37 have also been associated to other inflammatory 
disorders like lupus erythematosus, contact dermatitis or inflamed synovial membranes [20, 34]. Gilliet and Lande[35] 
proposed that these inflammatory disorders are caused by the inappropriate recognition of self-nucleic acids with 
induction of interferon responses by plasmacytoid dendritic cells (pDCs). In normal conditions self-DNA released by 
dying cells is unable to enter pDCs and is degraded rapidly by extracellular DNases. LL37 binds to self-DNA and forms 
aggregated particles that are resistant to degradation by DNases and able to enter pDCs through proteoglycan-mediated 
attachment of LL37 to the cell membrane and lipid-raft-mediated endocytosis. Aggregated self-DNA particles are 
retained in early endocytic compartments to trigger induction of interferons (IFNs) by activating endosomal toll-like 
receptor 9 (TLR9) as if they were viruses. Type I IFNs trigger local maturation of myeloid dendritic cell and activation 
of autoreactive T cells leading to the formation of psoriatic skin lesions. In this process, activated Th17 cells produce 
IL-22 and IL-17 that stimulate psoriatic keratinocytes to sustain the expression of cationic antimicrobial peptides 
(AMP) including LL37, which further forms complexes with self-DNA that is abundantly released in psoriatic skin 
lesions by apoptotic cells. As a result, LL37/self-DNA complexes constantly promote dendritic cell maturation and 
activation of autoreactive T cells, providing a self-sustaining feedback mechanism that amplifies and maintains 
autoimmune skin inflammation in psoriasis. Leung et al. measured the serum concentrations of LL37 in eczema 
children patients and reported that the concentration of the peptide increased with the eczema severity. They considered 
that LL37 might be a biomarker for the severity of childhood eczema [36].  
 The expression of LL37 is upregulated by several stimuli, such as pro-inflammatory cytokines, growth factors, 
nutrients, and bacterial products, especially at inflammation and repair sites. The mechanisms regulating the LL37 
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production are not fully understood. Recently, the roles of the vitamin D3 and the hypoxia response pathways in the 
regulation of LL37 production in leucocytes and keratinocytes have been described. Vitamin D3 is naturally produced in 
the skin during exposure to sunlight, and is activated by hydroxylases CYP27A1 and CYP27B1 to generate the 
biologically active 1,25-dihydroxyvitamin D3 [35], which is a potent inducer of the antimicrobial protein cathelicidin in 
isolated human keratinocytes, monocytes, neutrophils and gingival epithelial cells [37-39]. As sunlight induces 
immunosuppression increasing the vulnerability to infection, Vitamin D3, potentially to balance this effect, stimulates 
the synthesis of LL37 in skin and circulating phagocytic cells [40]. Morevoer, Hata et al. have reported that oral 
administration of vitamin D for 21 days induced cathelicidin production in atopic dermatitis lesional skin [41].   
Hypoxia-inducible transcription factor 1α (HIF1α) also plays an important role in LL37 cellular expression. In fact, 
HIF1α-null mouse neutrophils show a dramatic reduction in the levels of mouse cathelin-related antimicrobial peptide 
(CRAMP) [42]. Also, the siRNA knock down of HIF1α in human keratinocytes decreased the expression of hCAP18 
[43]. On the other hand, Stroinigg and Srivastava [44] reported that the human beta-defensin 2 (HBD-2), present in 
significant amounts in human milk, greatly increased LL37 expression in colon and breast epithelial cells. Moreover, 
the exposure of human primary bronchial epithelial cells to IL-4 and IL-13 cytokines during mucociliary differentiation 
increased mRNA expression of hCAP18/LL37 and hBD-2 [45]. 
 Finally, microorganisms can also regulate the expression of LL37. Bacterial products from both gram-positive and 
gram-negative bacteria were shown to increase LL37 production in cultured sinus epithelial cells [46]. Butyrate, a 
product of bacterial microflora in the colon, induces LL37 production [47]. LL37 cellular expression was also found to 
be augmented by Pseudomonas aeruginosa flagellin [48], fungal allergens in nasal tissue from chronic rhinosinusitis 
patients [49], and Helicobacter pylori in gastric epithelium [50]. On the other hand, other pathogens reduce the 
expression of the peptide: Shigella flexneri suppress LL37 production [51]; Neisseria gonorrhoeae, a human pathogen 
causing the sexually transmitted disease gonorrhoeae, that preferentially attach to and invade epithelial cells of the 
genital tract was found to down-regulate the expression of LL37, indicating that pathogenic Neisseria may gain a 
survival advantage in the female genital tract by decreasing LL37 expression [52]; Cholera toxin and labile toxin, the 
major virulence proteins of Vibrio cholerae and enterotoxigenic Escherichia coli, respectively, are predominantly 
responsible for the suppression of LL37 and human beta-defensin 1 (HBD-1) expression in intestinal epithelial cells 
both in vitro and in vivo [53]. 
2.2 Functions of LL37 
LL37 was initially recognized for its antimicrobial properties. Nevertheless, it has been found to have additional 
defensive roles such as regulating the inflammatory response and chemo-attracting cells of the adaptive immune system 
to wound or infection sites, binding and neutralizing LPS, promoting re-epthelialization and wound closure and more as 
illustrated in figure 3.  
 
Fig.3 Biological activities of LL37. 
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Antimicrobial activity 
 
The antibacterial activity of LL37 has mostly been studied in vitro using the synthetic peptide. The reported activities of 
LL37 vary in several studies, indicating that it is sensitive to differences in the experiment conditions, such as salt, pH 
and the phase of bacterial growth. Nevertheless, LL37 has a broad range of activity against both Gram-negative and 
Gram-positive bacteria. LL37 exhibits potent activity against Escherichia coli, Salmonella typhimurium and Salmonella 
minnesota, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Klebsiella pneumoniae and group A Streptococcus with 
MIC values of 0.6-7.6 μg/ml (0.1-2 μM) [54], 0.2-3.6 μg/ml (0.1-0.8 μM) [54], 0.9-5.7 μg/ml (0.2-1 μM) [54], 0.9 
μg/ml (0.2 μM) [52], 4.2 µg/ml (0.9 µM) [55], and 5-72 μg/ml (1-16 μM) [56] respectively, while low activity has been 
detected against the yeast Candida albicans (MIC >250 μg/ml or 56 μM) [57] and spirochaete (MIC>145 µg/ml or 32 
µM) [58]. Besides its low activity against C. albicans, LL37 was still able to reduce the C. albicans infectivity by 
inhibiting its adhesion to plastic surfaces, oral epidermoid cells, and urinary bladders of female BALB/c mice. The 
inhibitory effects of LL-37 on cell adhesion and aggregation were mediated by its preferential binding to mannan, the 
main component of the C. albicans cell wall, and partially by its ability to bind chitin or glucan, which underlie the 
mannan layer [59]. LL37 has also been shown to possess some antiviral activity against herpes simplex virus [60] and 
vaccinia virus [61] and inhibits HIV-1 replication in peripheral blood mononuclear cells, including primary CD4(+) T 
cells [62]. Additionally, LL37 inhibits the formation of P. aeruginosa bacterial biofilms [63]. Like most other AMPs, 
LL37 kills microorganisms by membrane disruption, resulting in lysis. By using solid-state NMR data and differential 
scanning calorimetry, Wildman et al. proposed that LL37 covers the surface of the membrane, resulting in toroidal pore 
formation with subsequent leakage of the cytoplasmic content [64]. LL37 can also be cytotoxic to eukaryotic cells, 
including both erythrocytes and leukocytes. However, the cytotoxic concentrations (>58 μg/ml or 13 μM) are generally 
higher than the concentrations required for elimination of microorganisms [65].  
 The MIC values of LL37 determined in vitro are similar with the physiological concentrations observed during 
infectious and inflammatory disorders. Several studies reported the antimicrobial activity of LL37 to be noticeably 
reduced in high salt concentrations, under serum conditions, in the presence of a lung surfactant preparation as well as 
in the presence of artificial tears. However, in vivo, LL37 acts together with other antimicrobial components, i.e. beta-
defensin 2 [66], lysozyme and lactoferrin [67], to show optimal killing capacity. Since the reported MIC values are 
determined for LL37 alone, there might be an underestimation of the antimicrobial activity under in vivo conditions, 
where synergistic effect with other antimicrobial components has to be considered. In fact, the role of LL37 in disease 
has been demonstrated in several reports. Nizet et al. [68] showed that mice with disrupted Cnlp, the gene coding for 
CRAMP (cathelin-related antimicrobial peptide), bear increased susceptibility to skin infections. Since CRAMP is 
similar to LL37 in structure, tissue distribution and antimicrobial activity, the CRAMP knockout model is a useful one 
for studying the function of the human cathelicidin. The in vivo role of LL37 in preventing infections is also supported 
by an observation made in patients with morbus Kostmann syndrome. These patients lack LL37 in the saliva 
neutrophils, which may contribute to increased susceptibility to oral infections. A different approach to evaluate the role 
of LL37 in certain diseases is to overexpress the peptide. As example, an adenovirus vector was utilized to transfer the 
LL37-gene systemically or into trachea of mice [69]. Furthermore, the vector was inserted into human bronchial 
xenograft, derived from patients with cystic fibrosis [70]. The overexpression of LL37 augmented the killing of bacteria 
in all these cases. 
 
Lipopolysaccharide neutralizing properties 
 
Lipopolysaccharides (LPS) endotoxins are heteropolymeric components of the outer layer membrane of Gram-negative 
bacteria with strong immunotoxic properties. LPS play an important role in pathogenesis of many exogenous 
respiratory diseases, including organic dust toxic syndrome and chronic illnesses such as chronic obstructive pulmonary 
disease, asthma or allergic alveolitis (hypersensitivity pneumonitis) [71]. LPS is released upon cell death, activating 
mononuclear phagocytes (monocytes and macrophages) to produce and release proinflammatory cytokines such as 
tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and others [72]. This event is initiated by binding of LPS to LPS-
binding protein (LBP), followed by a second binding of the LPS-LBP complex to CD14, the primary receptor of LPS, 
which is expressed mainly on macrophages [73]. The LPS-CD14 complex initiates intracellular signaling by interacting 
with the transmembrane protein Toll-like receptor-4 (TLR-4), which activates the NF-kB transcription factor, resulting 
in the production and secretion of pro-inflammatory cytokines [74]. The massive release of LPS can lead in extreme 
cases to endotoxic shock and therefore, death.  
 Some AMPs, including LL37, have the capacity to neutralize LPS by binding it with high affinity, inhibiting LPS 
interaction with LBP and/or CD14 [75, 76]. Another mechanism has also been suggested, where LL37 binds directly to 
CD14, inhibiting the association of LPS with its receptor. LL37 significantly inhibited the expression of specific 
proinflammatory genes upregulated by NF-kB in the presence of LPS in human monocytes [77]. It reduced TNF-α and 
nitric oxide levels produced by LPS and IFN-γ-polarized mouse bone marrow-derived macrophages [78]. Also, LL37 
suppressed the LPS-induced apoptosis of endothelial cells [79]. Kandler et al. showed that LL37 also blocked the effect 
of flagellin and lipoteichoic acid on dendritic cells [80]. The antiendotoxic effect of LL37 has been confirmed in vivo 
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using rat as a model system, making it a promising candidate for treatment of endotoxin shock or sepsis that is 
associated with a high rate of human death, for which there is yet no effective treatment [81]. 
 
Immunomodulatory properties 
 
In addition to its antimicrobial activity and ability to neutralize LPS, LL37 plays a central role in innate immunity. It is 
chemoattractant for mast cells [82], monocytes, T lymphocytes and neutrophils [83]. Formyl Peptide Receptor Like-1 
(FPRL-1) is the only receptor found to activate direct migration of immunological cells to a site of infection. As 
leukocytes participate in both innate and adaptive immunity, the fact that LL37 can chemoattract human leukocytes may 
provide one additional mechanism by which LL37 contributes to host defense against microbial invasion, by 
participating in the recruitment of leukocytes to sites of infection. This mechanism is potentially important in vivo, 
because the chemotactic activity of LL37, unlike its antimicrobial action, is not significantly inhibited by the presence 
of human serum. The activation of FPRL-1 requires relatively high concentrations of LL37 (10−5 M) when compared to 
other classical chemoattractant agents, suggesting a low-affinity peptide-receptor interaction [84]. This implies that 
cellular FPRL-1 mediated recruitment by LL37 in vivo may be active only when a threshold concentration of the 
peptide is reached following upregulation of the LL37 gene in epithelial cells or after massive release from invading 
neutrophils. Therefore, LL37 can potentially reach its optimal chemotactic concentration at local inflammatory sites. 
LL37 modulates cellular immune responses by stimulation of chemokine production. LL37 activates airway epithelial 
cells as demonstrated by activation of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated 
kinase (ERK) and increases release of the potent chemoattractant IL-8. LL37 transactivates the epidermal growth factor 
receptor (EGFR) via metalloproteinase-mediated cleavage of membrane-anchored EGFR-ligands [85]. LL37 also 
induces IL-8 secretion through phosphorylation and activation of the MAPKs, extracellular signal-regulated kinase 1/2 
(ERK1/2) in monocytes [86]. Human airway smooth muscle cells also respond to LL37 by releasing IL-8, suggesting 
that LL-37 is a regulator of the inflammatory process in various inflammatory lung diseases [87]. Yoshioka et al. [88] 
reported that LL37 also causes functional changes in mast cells. Mast cells in the skin are involved in the innate 
immune system response against microbial infections via Toll-like receptors (TLRs), such as TLR-4, which that is 
known to recognize LPS. They observed that LL37 increased the level of TLR-4 mRNA and TLR-4 protein, and 
induced the release of IL-4, IL-5 and IL-1β from mast cells. Additionally, mast cells show degranulation upon 
stimulation with LL37. Degranulation releases pro-inflammatory mediators, such as histamine and prostaglandins, into 
the surrounding tissue, thus increasing vascular permeabilization and promoting the infiltration of inflammatory cells 
[89]. LL37 also interacts with the purinoceptor P2X7, predominantly expressed on monocytes, macrophages and DCs 
and induces the processing and release of the potent cytokine IL-1β [90] and IL-8 in human gingival fibroblasts [91].  
 LL37 shows different effects on apoptotic cell death of different cell types. LL37 promotes apoptosis in various T-
cells, smooth muscle cells and epithelial cells, while it is a potent inhibitor of human neutrophil apoptosis [65, 92]. The 
inhibition of neutrophils apoptosis may be a survival strategy, leading to an increase of viable neutrophils at the site of 
infection, which is beneficial for the host during bacterial invasion. It has been proposed that the underlying mechanism 
for the inhibition of apoptosis by LL37 is mediated via FPRL-1 and P2X7 receptors, resulting in the inhibition of 
caspase 3 activity [93]. Lau et al. [94] reported that the apoptosis of airway epithelial cells is inhibited by human serum. 
Finally, Davidson et al. [95] identified LL37 as a potent modifier of dendritic cells differentiation, bridging innate and 
adaptive immune responses. LL-37-derived DCs displayed significantly up-regulated endocytic capacity, modified 
phagocytic receptor expression and function, up-regulated costimulatory molecule expression, enhanced secretion of 
Th-1 inducing cytokines, and promoted Th-1 responses in vitro. Moreover, when internalized by immature human DCs, 
LL37 caused phenotypic changes, characterized by an increased expression of the antigen-presenting molecule HLA-
DR, and the costimulatory molecule CD86 [96]. 
 
Angiogenesis and wound healing 
 
The healing of wound is a complex process that involves different steps: haemostasis, inflammation, 
remodeling/granulation tissue formation and re-epithelialization. Angiogenesis is critical to wound repair. Newly   
formed blood vessels participate in provisional granulation tissue formation and provide nutrition and oxygen to 
growing tissues. Angiogenesis, in response to tissue injury, is a dynamic process that is highly regulated by signals from 
both serum and the surrounding extracellular matrix environment [97].  
 LL37 is importantly involved in tissue healing processes, especially revascularization and cell growth. LL37 induces 
angiogenesis mediated by FPRL-1 expressed on endothelial cells. Koczulla et al. [98] reported that the application of 
LL37 stimulated neovascularization in a chorioallantoic membrane assay and in a rabbit model of hind-limb ischemia. 
The peptide directly activates endothelial cells, resulting in increased proliferation and formation of vessel-like 
structures in cultivated endothelial cells. Also, decreased vascularization during wound repair was observed in mice 
deficient for CRAMP. LL37 induces wound healing, proliferation, and migration of airway epithelial cells. Therefore, 
the peptide is likely involved in the regulation of tissue homeostasis in the airways [99]. It also promotes the migration 
of keratinocytes via EGFR transactivation [100]. More importantly, upon injury, a large increase in the expression of 
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cathelicidins in human and murine skin after sterile incision was observed and returned to normal levels as the wound 
closed [56]. The appearance of cathelicidins in skin was due to both synthesis within epidermal keratinocytes and 
deposition from granulocytes that migrate to the site of injury. In human burns, higher mRNA levels of hCAP18/LL37, 
hBD-2 and hBD-3 were detected [101]. The importance of LL37 in re-epithelialization was clearly demonstrated by 
Heilborn et al. [102]. The authors showed that the use of antibodies against LL37 inhibited re-epithelialization in a 
concentration-dependent manner in a non-inflammatory ex vivo wound healing model and that the peptide is lacking in 
chronic ulcers. In a recent work, Carretero et al. [103] demonstrated that LL37 significantly improved re-
epithelialization and granulation tissue formation by in vivo adenoviral transfer of the peptide to excisional wounds in 
ob/ob mice. According to Gronberg et al. the proteolytic environment of chronic wounds does not seem to prevent the 
therapeutic use of topical LL37. The authors showed that LL37 was not degraded by matrix metalloproteinase-9, and 
was fairly resistant to proteolytic cleavage ex vivo by incubation with wound fluid from non-healing venous leg ulcers 
[104]. Moreover, we have recently demonstrated that the topical application of recombinant LL37 produced in our 
laboratory [105] induced angiogenesis and re-epithelialization in wounds of dexamethasone-treated mice (paper 
submitted). 
     As already stated, LL37 promotes cells proliferation and angiogenesis. Unfortunately, angiogenesis is also necessary 
for cancerous tumors to keep growing and spreading. LL37 has emerged as a novel modulator of tumor growth and 
metastasis in carcinogenesis in ovarian, lung, breast and prostate cancers [106-109]. In fact, LL37 expression is 
upregulated in these tumors. However, in gastric cancer, the peptide inhibits cell proliferation [110]. LL37 also exhibits 
antitumor effects on epidermoid carcinoma cells, suggesting that the effect of LL37 on cancer phenotypes depends on 
the tissue origin of the tumor [111]. Although LL37 is demonstrated to promote cancer metastasis, fragments of the 
peptide have tumor inhibitory effects. These findings suggest that the fragments of LL37 have the potential to be 
developed into anticancer agents [112]. As an alternative strategy, LL37 has been shown to enhance the antitumor 
effects induced by CpG oligodeoxynucleotides (ODNs) through stimulating the tumor-suppressing activity of natural 
killer cells [113, 114]. Unmethylated CpG sites can be detected by TLR-9 on pDCs and B lymphocytes in humans to 
detect intracellular viral, fungal, and bacterial pathogen DNA, resulting in the secretion of proinflammatory cytokines, 
which may contribute to the immune response to the pathogen [115]. The potent immunostimulatory effects of TLR-9 
activation by CpG ODNs have resulted in enormous interest in the potential uses of these TLR-9 agonists as adjuvants 
for clinical therapy [116]. Hurtado and Peh reported that LL37 promotes the rapid sensing of CpG ODNs by B 
lymphocytes and pDCs but not T cells. These results are relevant to contemporary studies of TLR9 agonists as 
adjuvants for vaccines and cancer therapy [117]. 
3. Conclusion 
LL37 is a multifunctional host defense peptide. Besides its antimicrobial activity, it stimulates a complex group of 
responses in many cells, either directly or through modulation of cellular responses to microbial compounds and other 
immune mediators. A better understanding of the biological activity of LL37 and its interactions with other immune 
mediators will permit to create strategies and opportunities for therapeutic intervention in infectious and inflammatory 
diseases. 
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